Reported 2 days ago
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has shown strong performance with $825 million in Q2 2025 revenue, a 16% year-over-year increase. Analysts are generally optimistic, with Raymond James maintaining a Buy rating and a target price of $85, while Wedbush also supports the stock. However, H.C. Wainwright offers a more cautious Hold rating at a $60 target. Despite BMRN's potential, some analysts suggest that other AI stocks may present better investment opportunities.
Source: YAHOO